On September 14, Shanghai Upper Bio-Tech Pharma Co., Ltd. was listed on the National Equities Exchange and Quotations (NEEQ) in China market. The transaction method is call auction, and the level to which it belongs is the basic layer. The company transfers to NEEQ after withdrawing the application for listing on the SSE STAR Market. From the financial data, the company meets the fourth set of financial standards (R&D standards) for listing on the Beijing Stock Exchange.

Upper Bio-Tech was listed on the NEEQ and issued 3.94 million shares at a price of CNY 10.3 per share, raising CNY 40.59 million in total.

Upper 's end customers are concentrated in medical institutions at all levels,  and the main products are reagents and instruments. The company's revenue of 2020 and January to November in 2020 was CNY 143 million and CNY 128 million respectively, the net profit attributable to the parent was CNY 2.16 million and CNY 12.15 million. The company’s total R&D expenses were CNY 60.1 million.

Upper focuses on the research and development, production and sales of POCT detection instruments and POCT detection reagents. The company's products can be divided into two categories: reagent products and instrument products, which have been widely used in clinical medical fields such as inflammatory infection detection, infectious disease detection, cardiovascular and cerebrovascular detection, glucose metabolism detection, kidney disease detection, and prenatal and postnatal care detection.

The company has become one of the domestic in vitro diagnostic product suppliers with the combination of POCT products and informatization.